A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity Journal Article


Authors: Zhao, Y.; Wang, Q. J.; Yang, S.; Kochenderfer, J. N.; Zheng, Z.; Zhong, X.; Sadelain, M.; Eshhar, Z.; Rosenberg, S. A.; Morgan, R. A.
Article Title: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
Abstract: To generate chimeric Ag receptors (CARs) for the adoptive immunotherapy of cancer patients with ErbB2-expressing tumors, a single-chain Ab derived from the humanized mAb 4D5 Herceptin (trastuzumab) was initially linked to T cell signaling domains derived from CD28 and the CD3ζ to generate a CAR against ErbB2. Human PBLs expressing the 4D5 CAR demonstrated Ag-specific activities against ErbB2<sup>+</sup> tumors. However, a gradual loss of transgene expression was noted for PBLs transduced with this 4D5 CAR. When the CD3ζ signaling domain of the CAR was truncated or mutated, loss of CAR expression was not observed, suggesting that the CD3ζ signaling caused the transgene decrease, which was supported by the finding that T cells expressing 4D5 CARs with CD3ζ ITAM mutations were less prone to apoptosis. By adding 4-1BB cytoplasmic domains to the CD28-CD3ζ signaling moieties, we found increased transgene persistence in 4D5 CAR-transduced PBLs. Furthermore, constructs with 4-1BB sequences demonstrated increased cytokine secretion and lytic activity in 4D5 CAR-transduced T cells. More importantly, PBLs expressing this new version of the 4D5 CAR could not only efficiently lyse the autologous fresh tumor digests, but they could strongly suppress tumor growth in a xenogenic mouse model.
Keywords: protein expression; unclassified drug; human cell; nonhuman; antineoplastic agent; cd3 antigen; t lymphocyte; mouse; cell survival; interleukin 2; cancer immunotherapy; apoptosis; breast cancer; epidermal growth factor receptor 2; animal experiment; cyclophosphamide; antineoplastic activity; cancer cell culture; protein bcl xl; tumor necrosis factor alpha; human cell culture; gamma interferon; retrovirus vector; transgene; cytokine release; loss of function mutation; adoptive immunotherapy; natural killer cell receptor nkg2d; cd28 antigen plus cd3 sigma antigen plus trastuzumab; lysis
Journal Title: Journal of Immunology
Volume: 183
Issue: 9
ISSN: 0022-1767
Publisher: The American Association of Immunologists, Inc  
Date Published: 2009-11-01
Start Page: 5563
End Page: 5574
Language: English
DOI: 10.4049/jimmunol.0900447
PROVIDER: scopus
PUBMED: 19843940
PMCID: PMC6292203
DOI/URL:
Notes: --- - "Cited By (since 1996): 15" - "Export Date: 30 November 2010" - "CODEN: JOIMA" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Michel W J Sadelain
    514 Sadelain